Strs Ohio boosted its stake in shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 28.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 386,886 shares of the medical instruments supplier’s stock after buying an additional 85,558 shares during the quarter. Strs Ohio’s holdings in DENTSPLY SIRONA were worth $16,934,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Piedmont Investment Advisors LLC acquired a new position in DENTSPLY SIRONA during the 2nd quarter worth about $117,000. IBM Retirement Fund lifted its holdings in DENTSPLY SIRONA by 49.1% during the 1st quarter. IBM Retirement Fund now owns 4,955 shares of the medical instruments supplier’s stock worth $249,000 after buying an additional 1,631 shares during the period. NuWave Investment Management LLC lifted its holdings in DENTSPLY SIRONA by 184.6% during the 1st quarter. NuWave Investment Management LLC now owns 5,237 shares of the medical instruments supplier’s stock worth $263,000 after buying an additional 3,397 shares during the period. Northwest Investment Counselors LLC lifted its holdings in DENTSPLY SIRONA by 21.0% during the 2nd quarter. Northwest Investment Counselors LLC now owns 7,582 shares of the medical instruments supplier’s stock worth $332,000 after buying an additional 1,318 shares during the period. Finally, Koch Industries Inc. acquired a new position in DENTSPLY SIRONA during the 1st quarter worth about $385,000. 93.80% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Michael C. Alfano sold 1,404 shares of the company’s stock in a transaction that occurred on Wednesday, May 30th. The stock was sold at an average price of $45.83, for a total transaction of $64,345.32. Following the transaction, the director now directly owns 13,458 shares of the company’s stock, valued at approximately $616,780.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael J. Coleman sold 6,038 shares of the company’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $43.97, for a total value of $265,490.86. Following the transaction, the director now directly owns 26,960 shares in the company, valued at $1,185,431.20. The disclosure for this sale can be found here. 1.93% of the stock is currently owned by corporate insiders.
Shares of NASDAQ:XRAY opened at $38.67 on Friday. The stock has a market capitalization of $8.68 billion, a PE ratio of 14.54, a price-to-earnings-growth ratio of 2.26 and a beta of 1.27. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.69. DENTSPLY SIRONA Inc has a 1 year low of $37.70 and a 1 year high of $68.98.
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. DENTSPLY SIRONA had a positive return on equity of 9.12% and a negative net margin of 39.62%. During the same period in the previous year, the business earned $0.65 EPS. equities research analysts forecast that DENTSPLY SIRONA Inc will post 2.07 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 12th. Investors of record on Friday, September 28th will be paid a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, September 27th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is currently 13.16%.
XRAY has been the topic of several recent research reports. Deutsche Bank cut their target price on DENTSPLY SIRONA to $55.00 and set a “buy” rating on the stock in a report on Wednesday, May 16th. Stifel Nicolaus reissued a “buy” rating and issued a $57.00 price objective (down from $67.00) on shares of DENTSPLY SIRONA in a research note on Tuesday, May 8th. Jefferies Financial Group dropped their price objective on DENTSPLY SIRONA from $58.00 to $46.00 and set a “buy” rating on the stock in a research note on Wednesday, August 8th. TheStreet downgraded DENTSPLY SIRONA from a “c-” rating to a “d+” rating in a research note on Tuesday. Finally, Stephens downgraded DENTSPLY SIRONA from an “overweight” rating to an “equal weight” rating and set a $75.00 price objective on the stock. in a research note on Wednesday, August 8th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $52.18.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Recommended Story: Stock Symbol
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc (NASDAQ:XRAY).
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.